11β-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation

Hypertension

Volumn 48, Issue 1, 2006, Pages 127-133

  Zhang, Zhi Hua ^a   Kang, Yu Ming ^a   Yu, Yang ^a   Wei, Shun Guang ^a   Schmidt, Thomas J ^a   Johnson, Alan Kim ^a   Felder, Robert B ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Aldosterone; Brain; Corticosterone

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; CARBENOXOLONE; CORTICOSTERONE; ENZYME INHIBITOR; GLYCYRRHIZIC ACID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; MESSENGER RNA;

ADRENALECTOMY; ADRENERGIC SYSTEM; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HEART RATE; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; REAL TIME POLYMERASE CHAIN REACTION; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ALDOSTERONE; ANIMALS; CARBENOXOLONE; GLYCYRRHIZIC ACID; MALE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER;

EID: 33746022627     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000224296.96235.dd     Document Type: Article

References (44)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
2. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53-58.
3. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol. 2001;281:H2241-H2251.
4. Lal A, Veinot JP, Leenen FH. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res. 2004;64:437-447.
5. Francis J, Weiss RM, Johnson AK, Felder RB. Central mineralocorticoid receptor blockade decreases plasma TNF-α after coronary artery ligation in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R328-R335.
6. Grillo C, Vallee S, McEwen BS, De Nicola AF. Properties and distribution of binding sites for the mineralocorticoid receptor antagonist [3H]ZK 91587 in brain. Journal of Steroid Biochemistry. 1990;35:11-15.
7. de Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, de Jong W. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int. 2000;57:1329-1336.
8. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Is aldosterone synthesized within the rat brain? Am J Physiol Endocrinol Metab. 2005;288:E342-E346.
9. Robson AC, Leckie CM, Seckl JR, Holmes MC. 11β-Hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Brain Res Mol Brain Res. 1998;61:1-10.
10. Roland BL, Li KX, Funder JW. Hybridization histochemical localization of 11 β-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology. 1995;136:4697-4700.
11. Geerling JC, Kawata M, Loewy AD. Aldosterone-sensitive neurons in the rat central nervous system. J Comp Neurol. 2006;494:515-527.
12. Geerling JC, Engeland WC, Kawata M, Loewy AD. Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite. J Neurosci. 2006;26:411-417.
13. Han F, Ozawa H, Matsuda K, Nishi M, Kawata M. Colocalization of mineralocorticoid receptor and glucocorticoid receptor in the hippocampus and hypothalamus. Neurosci Res. 2005;51:371-381.
14. Am Physiological Society. Guiding principles for research involving animals and human beings. Am Journal of Physiology. 2002;283:R281-R283.
15. Duax WL, Ghosh D, Pletnev V. Steroid dehydrogenase structures, mechanism of action, and disease. Vitam Horm. 2000;58:121-148.
16. Hewitt A, Barrie R, Graham M, Bogus K, Leiter JC, Erlichman JS. Ventilatory effects of gap junction blockade in the RTN in awake rats. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1407-R1418.
17. Spataro LE, Sloane EM, Milligan ED, Wieseler-Frank J, Schoeniger D, Jekich BM, Barrientos RM, Maier SF, Watkins LR. Spinal gap junctions: potential involvement in pain facilitation. J Pain. 2004;5:392-405.
18. Gomez-Sanchez EP, Gomez-Sanchez CE. Maternal hypertension and progeny blood pressure: role of aldosterone and 11β-HSD. Hypertension. 1999;33:1369-1373.
19. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol. 1992;263:E1125-E1130.
20. Li YF, Cornish KG, Patel KP. Alteration of NMDA NR1 receptors within the paraventricular nucleus of hypothalamus in rats with heart failure. Circ Res. 2003;93:990-997.
21. Francis J, Chu Y, Johnson AK, Weiss RM, Felder RB. Acute myocardial infarction induces hypothalamic cytokine synthesis. Am J Physiol Heart Circ Physiol. 2004;286:H2264-H2271.
22. Chu Y, Heistad DD, Knudtson KL, Lamping KG, Faraci FM. Quantification of mRNA for endothelial NO synthase in mouse blood vessels by real-time polymerase chain reaction. Arterioscler Thromb Vasc Biol. 2002;22:611-616.
23. Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin- aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol. 2002;283:H423-H433.
24. Paxinos G, Watson C. The Rat Brain Is Stereotaxic Coordinates. Sydney, Australia: Academic Press; 1986.
25. Fitts DA, Thornton SN, Ruhf AA, Zierath DK, Johnson AK, Thunhorst RL. Effects of central oxytocin receptor blockade on water and saline intake, mean arterial pressure, and c-Fos expression in rats. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1331-R1339.
26. Grippo AJ, Na ES, Johnson RF, Beltz TG, Johnson AK. Sucrose ingestion elicits reduced Fos expression in the nucleus accumbens of anhedonic rats. Brain Res. 2004;1019:259-264.
27. Kageyama Y, Suzuki H, Saruta T. Role of glucocorticoid in the development of glycyrrhizin-induced hypertension. Clin Exp Hypertens. 1994;16:761-778.
28. Elijovich F, Kirchberger M, Barry CR, Krakoff LR. Maintenance of arterial pressure by vasopressin and angiotensin II after adrenalectomy. Hypertension. 1983;5:V53-V56.
29. Stith RD, Bhaskar M, Reddy YS, Brackett DJ, Lerner MR, Wilson MF. Cardiovascular changes in chronically adrenalectomized conscious rats. Circ Shock. 1989;28:395-403.
30. Chen QH, Toney GM. Identification and characterization of two functionally distinct groups of spinal cord-projecting paraventricular nucleus neurons with sympathetic-related activity. Neuroscience. 2003;118:797-807.
31. Swanson LW, Kuypers HG. The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol. 1980;194:555-570.
32. Pyner S, Coote JH. Identification of branching paraventricular neurons of the hypothalamus that project to the rostroventrolateral medulla and spinal cord. Neuroscience. 2000;100:549-556.
33. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26:313-321.
34. Alzamora R, Michea L, Marusic ET. Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension. 2000;35:1099-1104.
35. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005;70:347-351.
36. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227-1235.
37. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol. 1990;258:E649-E653.
38. Funder JW. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol. 2004;217:263-269.
39. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM. Tumor necrosis factor α and phorbol 12-myristate-13-acetate down-regulate human 11β-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-κB homodimers and Egr-1. Faseb J. 2005;19:650-652.
40. Heiniger CD, Kostadinova RM, Rochat MK, Serra A, Ferrari P, Dick B, Frey BM, Frey FJ. Hypoxia causes down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. Faseb J. 2003;17:917-919.
41. Lanz B, Kadereit B, Ernst S, Shojaati K, Causevic M, Frey BM, Frey FJ, Mohaupt MG. Angiotensin II regulates 11β-hydroxysteroid dehydrogenase type 2 via AT2 receptors. Kidney Int. 2003;64:970-977.
42. Tan J, Wang H, Leenen FH. Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol Heart Circ Physiol. 2004;286:H1665-H1671.
43. Yu Y, Wei SG, Zhang Z-H, Chu Y, Weiss RM, Felder RB. Oral eplerenone inhibits the central effects of tumor necrosis factor-α on 11β-hydroxysteroid dehydrogenase type 2 gene expression in heart failure rats. Circulation. 2005;112:II-191.Abstract.
44. Francis J, Beltz T, Johnson AK, Felder RB. Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-α in normal rats. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1402-R1409.